Patents
Literature
59 results about "Neurological disorder" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A type of nervous system disorder that affects brain and neurons.
Transferrin receptor binding molecules, their conjugates, and their use for the prevention or treatment of neurological disorders.
The present invention relates to variable domains (VHHs) of camelid heavy chain molecules that bind to TfR, conjugate compounds containing such VHH molecules, and their use for, for example, transporting molecules for pharmaceutical purposes to cells and organs in pathological conditions in the CNS or PNS, including cancer.
Owner:VECTOR-ALL +2
Sublingual or buccal dosage forms comprising antioxidants for treatment of central nervous system disorders
ActiveUS20260151332A1Organic active ingredientsNervous disorderTraumatic brain damagePharmaceutical medicine
Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.
Owner:BEYOND BARRIERS THERAPEUTICS INC
Ready to use non-aqueous solutions of lamotrigine
ActiveUS12661360B2Pharmaceutical delivery mechanismPharmaceutical non-active ingredientsTriazineSolvent
Disclosed are ready to use non-aqueous solutions of lamotrigine. The lamotrigine is dissolved in a solvent, wherein the solvent comprises propylene glycol and optionally at least one co-solvent, and wherein if water is present in the ready to use non-aqueous solution, the water is not at least one co-solvent. Also disclosed are methods for treating a neurological disorder or a mental disorder by administering the ready to use non-aqueous solutions of lamotrigine, processes for preparing ready to use non-aqueous solutions of lamotrigine, and kits containing lamotrigine to prepare ready to use non-aqueous solutions of lamotrigine.
Owner:TULEX PHARMACEUTICALS INC
S1P₁ receptor agonists and their uses
The present invention relates to a compound of the chemical formula (1a): (1a) The invention relates to or its enantiomers, racemic mixtures, or pharmaceutically acceptable salts. The invention also relates to a pharmaceutical composition comprising a compound of formula (1a), its enantiomers, racemic mixtures, or pharmaceutically acceptable salts, and one or more pharmaceutically acceptable excipients, and a method for treating autoimmune diseases, central nervous system diseases, and leukocyte disorders, comprising the step of administering the pharmaceutical composition of the invention to an individual in need.
Owner:VALO HEALTH INC
Compounds for the treatment of a central nervous system disease or disorder
Disclosed herein are substituted compounds, salts, and pharmaceutical formulations thereof, for the treatment of a central nervous system disease or disorder.
Owner:CORETERRA THERAPEUTICS INC
Novel irisin peptides and methods of use thereof
PendingUS20260139023A1Hormone peptidesCell receptors/surface-antigens/surface-determinantsDiseaseNeuron cell death
The present invention provides novel irisin peptides (e.g, irisin glycosylation mutants and biologically active fragments thereof). Also provided are methods for preventing or reducing degeneration of dopaminergic neurons and / or preventing or ameliorating at least one motor deficit in a subject in need thereof, such as in a subject with α-synucleinopathy, using the novel irisin peptides to modulate irisin-induced integrin signaling. The novel irisin peptides can also be used in methods for increasing expression of brain-derived neurotrophic factor (BDNF), and / or treating or preventing neurological diseases or disorders that would benefit from decreased neuronal cell death and / or increased neuronal survival in a subject. In addition, the novel irisin peptides may be used in methods for preventing or treating muscular atrophy or muscular dystrophy.
Owner:DANA FARBER CANCER INSTITUTE INC
Antibodies with fc modifications and methods of using the same
The disclosure features anti-tumor necrosis factor receptor superfamily (TNFRSF), anti-tumor necrosis factor superfamily (TNFSF), anti-CD28, and anti-ICOS antibodies and antigen-binding fragments thereof with amino acid modifications at the Fc domain, and the use of these antibodies or antigen-binding fragments to modulate immune response. The antibodies and antigen-binding fragments thereof can be used to treat a wide variety of cancers, autoimmune disorders, neurological disorders, infectious diseases, inflammatory diseases, and transplant rejections.
Owner:THE GENERAL HOSPITAL CORP
Nanobody Nb.TB1, engineered plant exosomes, their preparation methods and applications
PendingCN122080199AImprove traversal efficiencyefficient loadingNervous disorderImmunoglobulins against animals/humansNeurological disorderSortase A
This invention discloses a nanobody Nb.TB1, engineered plant exosomes, their preparation methods, and applications, belonging to the field of biomedical technology. The amino acid sequence of the nanobody Nb.TB1 is shown in Seq ID No. 1. Furthermore, this invention proposes a method for preparing engineered plant exosomes, comprising the following steps: S1, extraction of Gastrodia elata exosomes: extracting Gastrodia elata exosomes from Gastrodia elata using an enzymatic method; S2, expression and purification of the blood-brain barrier-crossing nanobody fusion protein with Sortase A ligase; S3, surface modification of the Gastrodia elata exosomes. In addition, this invention also proposes an engineered plant exosome prepared by the above method. Furthermore, this invention proposes the application of the above-mentioned engineered plant exosomes in the preparation of targeted therapeutic drugs for central nervous system diseases. The engineered plant exosomes prepared by this invention exhibit high blood-brain barrier crossing efficiency.
Owner:HUAZHONG AGRI UNIV
NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS
The present application relates to compounds of Formula (I), wherein P, Q, A, B, m, n, R1, R2 and R3 are defined as in Formula (I) which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The application is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00001.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00002.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
![NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS](https://images-eureka.patsnap.com/patent_img/4e0cf8e5-3fba-43e3-8151-d29a3a8f8ec5/US20260184715A1-C00003.png "NOVEL PYRROLO[1,2-d][1,2,4] TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS")
Owner:ADDEX PHARMACEUTICALS SA
(R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazin-1-carboxylate crystalline, compositions and methods of use thereof
Pharmaceutical forms comprising the crystalline forms of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate and their use in methods for treating diseases and disorders, including inflammatory bowel disease, neurological disorders, or cancer, are provided herein, wherein the method comprises administering the pharmaceutical forms to a patient in need.
Configuration of cerebellar closed loop neurostimulation using biomarkers
Owner:BAYLOR COLLEGE OF MEDICINE
Positive allosteric modulators of the muscarinic acetylcholine receptor m1
PendingUS20260138978A1Organic active ingredientsIsotope introduction to heterocyclic compoundsDiseasePyrazine
N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a tertiary alcohol-containing group substituted on the biarylmethylene are positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChRM1). The compounds and pharmaceutical compositions may be used in treating neurological disorders, psychiatric disorders, or a combination thereof.
Owner:VANDERBILT UNIV
Aza cyclic derivative inhibitors, methods of making and using same
PendingCN122103094ANervous disorderGroup 5/15 element organic compoundsDepressantPharmaceutical drug
The present invention relates to azacyclic derivative inhibitors, methods of making and using the same. In particular, the present invention relates to compounds of the general formula, methods of making the same, pharmaceutical compositions containing the same, and uses of the same in the treatment of central nervous system disorders.
Owner:JIANGSU HANSOH PHARMA CO LTD +1
Levodopa infusion solution
An aqueous pharmaceutical solution for the treatment of a central nervous system (CNS) disorder is provided, the solution comprising at least 5 mg / ml dissolved levodopa and a pH in the range of 3.0 to 8.5. The solution is provided by mixing: a) an aqueous stock solution comprising levodopa, the stock solution having a pH of less than 2.8 at 25°C, and b) an aqueous buffer solution for increasing the pH of the stock solution, the buffer solution having a pH of at least 4.0 at 25°C. The aqueous pharmaceutical solution is administered to a subject having a central nervous system (CNS) disorder shortly after mixing the aqueous stock solution and the aqueous buffer solution. Further, a kit for administering an aqueous pharmaceutical solution to a subject having a central nervous system (CNS) disorder is provided.
Owner:DIZLIN PHARMA AB
In vitro models for human neurological diseases
The present invention relates to a method for the preparation of an in vitro model for a human neurological disorder. Moreover, the invention relates to the in vitro model, produced according to the inventive method disclosed herein. In addition, the invention relates to the use of the in vitro model of the invention in drug testing. In addition, the invention relates to methods for testing the efficacy of drugs in the prevention, delay and amelioration of a human neurological disorder.
Owner:CLAVAGUERA FLORENCE
Monoacylglycerol Lipase Modulators
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.
Owner:JANSSEN PHARMA NV
Dcaf1 ligands and uses thereof
This disclosure provides small molecule pyrrole-3-carboxamide compounds, compositions thereof, and methods of using them to modulate DCAF1 and treat a variety of diseases, disorders or conditions associated with DCAF1, such as neurological disorders like Alzheimer's disease, Parkinson's disease or Huntington's disease, transplant rejection, AIDS-related Kaposi's sarcoma, and particularly cancer.
Owner:KEMERA THERAPEUTICS
Suppression of neurodegenerative diseases by single domain antibody
PendingUS20260139041A1Organic active ingredientsNervous disorderNervous systemAntiendomysial antibodies
The present invention is directed to methods for treating or preventing neuroinflammation in a subject by administering an effective amount of a single-domain antibody (sdAb) comprising SEQ ID NO:1. The method is applicable to subjects with multiple sclerosis, including secondary progressive, primary progressive, and relapsing-remitting forms. Administration may be intravenous, subcutaneous, or intrathecal, with dosage regimens including daily administration, loading and maintenance doses, or continuous infusion. The method may be initiated upon first clinical signs of central nervous system demyelination and continued for at least 14 days. The sdAb may be co-administered with a pharmaceutically acceptable excipient such as mannitol, sucrose, or polysorbate 80, and optionally combined with disease-modifying therapies including interferon-β, glatiramer acetate, fingolimod, or ocrelizumab. The invention provides a targeted approach for modulating neuroinflammatory processes in neurological disorders.
Owner:THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES
M1 microglia-targeting fusion peptide and use thereof
PCT designated stageWO2026105876A1Nervous disorderPeptide/protein ingredientsTarget peptideApoptosis induction
The purpose of the present invention is to provide a novel means that targets M1 microglia and is useful for the treatment of central nervous system diseases and the like. Provided is an M1 microglia-targeting fusion peptide in which an M1 microglia-targeting peptide and an apoptosis-inducing peptide are directly or indirectly linked to each other, wherein the M1 microglia-targeting peptide is a peptide mentioned in (1) or (2): (1) a peptide which has a structure such that at least one cysteine residue is directly linked to each of both ends of the amino acid sequence represented by HHSSSAR (SEQ ID NO: 1) or an amino acid sequence formed by linking a plurality of the sequences; and (2) a peptide which comprises an amino acid sequence having a structure such that one amino acid residue is or a plurality of amino acid residues are deleted, substituted or added in the amino acid sequence for the peptide (1) and which targets M1 microglia.
Owner:NAT UNIV CORP SHIGA UNIV OF MEDICAL SCI
Manual dexterity training device
The present disclosure provides a manual dexterity training device that addresses cognitive and motor skill decline through progressive therapeutic exercises. The device comprises an object configured to be manually moved, and a container with an open face defining side-A and side-B. A central vertical divider separates the sides and includes a protruding section with holes extending through face-A and face-B. Cover-A and cover-B are hingedly coupled to move between horizontal and vertical positions, each including holes for object passage. The device enables objects to move from side-A to side-B through aligned holes, providing graduated difficulty levels that help maintain independence and cognitive function in aging populations and individuals with neurological conditions.
Owner:STRAHAN MERRY
Composition for treating neurological disorders
This document describes a combination composition of compound 1 and fesoterodine for treating neurological disorders (e.g., schizophrenia, Alzheimer's disease psychosis, Parkinson's disease psychosis, cognitive impairment in Alzheimer's disease, psychosis in Lewy body dementia, bipolar disorder, and dyskinesia).
Owner:MAPLIGHT THERAPEUTICS INC
Treatment of bacterial infections in the central nervous system and associated neurological disorders in animals
The present disclosure relates to methods of control, treatment and / or prevention of a neurological disease or disorder in animals, optionally livestock, comprising administering a therapeutically effective amount of a fluoroquinolone compound, optionally pradofloxacin, or a pharmaceutically acceptable salt, solvate, hydrate or hydrate of salt thereof, wherein the neurological disease or disorder is caused by a bacterial infection in the central nervous system. The present disclosure further provides a method of control, treatment and / or prevention of a bacterial infection in the central nervous system in animals, optionally livestock, comprising administering a therapeutically effective amount of a fluoroquinolone compound, optionally pradofloxacin, or a pharmaceutically acceptable salt, solvate, hydrate or hydrate of salt thereof.
Owner:ELANCO US INC
Controlled transmucosal release of DMT in combination with a monoamine oxidase inhibitor
Pharmaceutical compositions for the transmucosal delivery of N-N-dimethyltryptamine (DMT) acceptable salt or prodrug thereof in combination with a monoamine oxidase inhibitor to achieve desired bioavailability suitable for the treatment of neurological disorders.
Owner:ATAI THERAPEUTICS INC
Compositions and methods for treatment of neurological disorders
Long-acting glucagon like peptide 1 receptor agonists (GLP-1r agonists) reduce and inhibit pathological processes that give rise to long-term neurological impairment. A biotinylated and / or lipidated GLP-1r agonist analogs with enhanced enzymatic stability needed for gastrointestinal absorption, improved bioavailability and pharmacokinetics are described. In preferred embodiments, the GLP-1r agonist analogs have the amino acid sequence of any one of SEQ ID NOs: 9-35. The compositions are typically administered via oral or parenteral routes. The compositions are particularly suited for treating, alleviating, and / or preventing one or more neurological diseases or disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD). Methods of treating a human subject having AD or PD or at risk of AD or PD are provided.
Owner:D&D PHARMATECH INC
AAV formulation
The disclosure provides a composition comprising recombinant adeno-associated virus (AAV) vectors comprising a heterologous nucleic acid, sodium chloride, potassium chloride, magnesium chloride, phosphate buffer, and a non-ionic surfactant, at pH of 7.2-7.4. The disclosure further provides a method of treating a neurological disorder in a subject, the method comprising directly administering to the central nervous system of a subject in need thereof the composition.
Owner:ENCODED THERAPEUTICS INC
Neurosteroid derivative solid dispersion, and preparation method and use thereof, and therapeutic drug for central nervous system disorder-related condition
Provided are a neurosteroid derivative solid dispersion, and a preparation method and use, and a drug containing a hot-melt extruded solid dispersion. A raw material mixture is subjected to melt extrusion at 125° C. to 160° C. to obtain the neurosteroid derivative solid dispersion, where the raw material mixture includes an active ingredient, a plasticizer and a carrier material, a mass ratio of the three being in a range of 10:1-15:10-90; the active ingredient includes at least one selected from the group consisting of a neurosteroid derivative (having a structure represented by formula 1), and an isomer, a solvate and a pharmaceutically acceptable salt thereof; the plasticizer is one or more selected from the group consisting of polyethylene glycol, poloxamer and Tween, the polyethylene glycol having an average molecular weight of less than 6000; and the active ingredient is present in an amorphous state.
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD
Magnesium-serinate compound and use thereof
The present invention relates to a novel magnesium-serinate compound and the use thereof, and more particularly, to a novel magnesium-serinate compound in which a magnesium atom is chelated to L-serine, and the pharmaceutical use thereof against central nervous system diseases or the like.
Owner:ASTROGEN CO LTD